None of these antibodies was specifically associated with lung involvement in SLE or scleroderma, but a trend was found towards an increase in all autoantibodies in association with lung disease in SLE, while the reverse trend was seen in scleroderma.
Accepted for publication 1 June 1989 Cryptogenic fibrosing alveolitis is known to occur alone or in association with autoimmune rheumatic diseases. Immunological abnormalities are commonly found in patients in whom fibrosing alveolitis is associated with these diseases, but also occur in patients with fibrosing alveolitis alone ('lone' fibrosing alveolitis). Chapman et al reported positive antinuclear antibodies in 46% of patients with fibrosing alveolitis with connective tissue disease, compared with 21% of patients with 'lone' fibrosing alveolitis, and 6% of normal control subjects. ' Conversely, within specific categories of autoimmune rheumatic disease, lung involvement with the histological features of fibrosing alveolitis may only affect some patients.2 It is thus pertinent to ask whether the development of fibrosing alveolitis in these patients is related to their autoantibody profile.
Antinuclear Among the patients with SLE, antibodies binding to double and single stranded DNA were more prevalent among patients with lung involvement, though the difference was only significant (p<OO5) for IgG antibodies to dsDNA. Indeed, there was a trend towards higher prevalence of all antibodies in those with lung involvement compared with those without (fig 2) . Interestingly, the reverse trend was seen in the patients with scleroderma. Here, autoantibodies, especially IgG and IgA isotypes of rheumatoid factor, and IgG anti-DNA antibodies, were mainly found in the patients who did not have fibrosing alveolitis (fig 3) .
Discussion
In this study none of the autoantibodies or idiotypes that was measured emerged as a marker for fibrosing alveolitis in SLE or scleroderma, as Jo-I appears to in polymyositis.
Nevertheless, there was a trend towards an increase in all of the antinuclear antibodies in association with lung disease in SLE, while the reverse trend was seen in scieroderma. There are several possible explanations for this finding.
In SLE active disease is reported to be associated with a rise in titre of certain autoantibodies. For example, high titres of antidsDNA antibodies are often seen in active renal disease. In our group of patients those with lung involvement might also have had more active disease. By contrast, those in the group with scleroderma with fibrosing alveolitis might have been less active at the time of study. n Alternatively, the difference may reflect different pathogenesis of lung involvement in SLE and scleroderma. Immune complex deposition resulting in fibrosing alveolitis in SLE might be expected to occur in the presence of increased immunoglobulin synthesis, reflected particularly in increased levels of IgG antibodies to ssDNA and dsDNA. In scleroderma, on the other hand, increased fibroblastic activity, producing a similar end result of fibrosing alveolitis, may occur by an entirely different mechanism.
Finally, the differences may simply reflect the comparatively small number of patients in some of the groups. With these small numbers only trends rather than statistical differences could be found. If there was a true difference between the groups one might also have expected to see a difference in antibody titres between the groups with and without fibrosing alveolitis, and this was not found.
These results suggest that although none of the autoantibodies or idiotypes measured here were specifically associated with the presence of fibrosing alveolitis in SLE or scleroderma, there may be more generalised differences in the autoantibody profiles of patients with and without lung involvement, and these may reflect activity of disease, or the mechanisms by which fibrosing alveolitis is produced. A larger study, encompassing a wider range of autoantibodies, is clearly indicated.
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